Compile Data Set for Download or QSAR
Report error Found 52 Enz. Inhib. hit(s) with all data for entry = 50010965
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543836(CHEMBL4637711)
Affinity DataIC50: 0.784nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543827(CHEMBL4638046)
Affinity DataIC50: 1.10nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543827(CHEMBL4638046)
Affinity DataIC50: 1.30nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543819(CHEMBL4639148)
Affinity DataIC50: 1.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543833(CHEMBL4634034)
Affinity DataIC50: 1.90nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543837(CHEMBL4641191)
Affinity DataIC50: 2nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543831(CHEMBL4637497)
Affinity DataIC50: 2nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543830(CHEMBL4642480)
Affinity DataIC50: 2.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543836(CHEMBL4637711)
Affinity DataIC50: 2.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543819(CHEMBL4639148)
Affinity DataIC50: 2.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543838(CHEMBL4633158)
Affinity DataIC50: 2.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50261028(CHEMBL3398466)
Affinity DataIC50: 2.80nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543833(CHEMBL4634034)
Affinity DataIC50: 2.90nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543834(CHEMBL4637671)
Affinity DataIC50: 3.10nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543839(CHEMBL4644984)
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543817(CHEMBL4645974)
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543840(CHEMBL4634476)
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50261028(CHEMBL3398466)
Affinity DataIC50: 3.20nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543817(CHEMBL4645974)
Affinity DataIC50: 3.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543839(CHEMBL4644984)
Affinity DataIC50: 3.30nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543829(CHEMBL4646361)
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543829(CHEMBL4646361)
Affinity DataIC50: 3.40nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543826(CHEMBL4645246)
Affinity DataIC50: 3.5nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543832(CHEMBL4643960)
Affinity DataIC50: 3.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543838(CHEMBL4633158)
Affinity DataIC50: 3.80nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543837(CHEMBL4641191)
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543831(CHEMBL4637497)
Affinity DataIC50: 4nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543832(CHEMBL4643960)
Affinity DataIC50: 4.5nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543840(CHEMBL4634476)
Affinity DataIC50: 4.60nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543825(CHEMBL4633255)
Affinity DataIC50: 4.60nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543830(CHEMBL4642480)
Affinity DataIC50: 5.40nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543835(CHEMBL4646165)
Affinity DataIC50: 5.40nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543821(CHEMBL4644741)
Affinity DataIC50: 8.10nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543821(CHEMBL4644741)
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543834(CHEMBL4637671)
Affinity DataIC50: 12nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543825(CHEMBL4633255)
Affinity DataIC50: 13nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543826(CHEMBL4645246)
Affinity DataIC50: 15nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543820(CHEMBL4633205)
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543841(CHEMBL3398482)
Affinity DataIC50: 21nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543841(CHEMBL3398482)
Affinity DataIC50: 39nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543820(CHEMBL4633205)
Affinity DataIC50: 52nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543824(CHEMBL4633992)
Affinity DataIC50: 61nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543835(CHEMBL4646165)
Affinity DataIC50: 86nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543823(CHEMBL4633683)
Affinity DataIC50: 133nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543823(CHEMBL4633683)
Affinity DataIC50: 149nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543828(CHEMBL4645946)
Affinity DataIC50: 274nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543818(CHEMBL4635632)
Affinity DataIC50: 313nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543828(CHEMBL4645946)
Affinity DataIC50: 344nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin/Hypocretin receptor type 1(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543818(CHEMBL4635632)
Affinity DataIC50: 363nMAssay Description:Antagonist activity at human recombinant OX1R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
TargetOrexin receptor type 2(Human)
Taisho Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50543824(CHEMBL4633992)
Affinity DataIC50: 2.30E+3nMAssay Description:Antagonist activity at human recombinant OX2R expressed in CHOK1 cells assessed as inhibition of orexin A-induced intracellular Ca2+ release preincub...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/13/2021
Entry Details Article
PubMed
Displayed 1 to 50 (of 52 total ) | Next | Last >>
Jump to: